Alerts in the last 24 hours

No Personalised Alerts!

To see personalised alerts you need to be logged in.

Log In

Eli Lilly and Company Add to portfolio

INX:LLY, Aug 20, 05:13 UTC

Latest INX:LLY News

Filter your feed

Apply Filter

Yesterday


News

UPDATE 1-Roche taps Lilly executive Garraway as chief medical officer

LLY

UPDATE 1-Roche taps Lilly executive Garraway as chief medical officer. ZURICH, Aug 19 (Reuters) - Swiss drugmaker Roche Holding on Monday named Eli Lilly executive Levi Garraway to succeed Sandra Horning as chief medical officer and head of global product development. Garraway, most recently Eli Lilly's senior vice president, oncology research and development and Lilly research laboratories novel target research, will take up the post as of Oct. 1 and be based in South San Francisco. Horning, who joined Roche and its Genentech division nearly a decade ago and has been chief medical officer since 2014, will retire as of the end of 2019, Roche said in a statement.

Read Full Details

Topics:
  • Business
  • Health
  • Financial
News

Dupont Capital Management Corp Decreases Holdings in Eli Lilly And Co (NYSE:LLY) – Riverton Roll

LLY

Dupont Capital Management Corp lessened its stake in Eli Lilly And Co (NYSE:LLY) by 32.7% in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. Edward Jones upgraded Eli Lilly And Co from a “hold” rating to a “buy” rating and set a $117.49 price objective on the stock in a report on Tuesday, April 23rd. In other Eli Lilly And Co news, CFO Joshua L. Smiley bought 426 shares of Eli Lilly And Co stock in a transaction dated Wednesday, June 5th. Following the purchase, the chief financial officer now owns 30,410 shares of the company’s stock, valued at approximately $3,589,292.30.

Read Full Details

Topics:
  • Business
  • Health
  • Financial
News

Global Injectable Drug Delivery Market Key Players 2019 – Baxter International, Inc., Becton, Dickinson And Company, Gerresheimer Ag – SteerVibes

LLY

The report likewise incorporates a point by point improvement of the key merchants working in this market. Regional Analysis For Injectable Drug Delivery Market:. North America (United States, Canada and Mexico)Europe (Germany, France, UK, Russia and Italy)Asia-Pacific (China, Japan, Korea, India and Southeast Asia)South America (Brazil, Argentina, Colombia etc. The Global Injectable Drug Delivery Market Is Classified On The Basis Of Product Type: Product Type Segmentation : Ampules, Vials, Cartridges, Bottles Industry Segmentation Hospitals And Clinics, Home Care SettingsChannel Segmentation : Direct Sales, Distributor. Key Reasons to Purchase–1) The competitive Injectable Drug Delivery Industry structure is profiled to represent market size, status, revenue and market share.2) The forward-looking Injectable Drug Delivery industry perspective states the market value, consumption and market share analysis3) The forecast statistics will provide analysis of Injectable Drug Delivery Market drivers, growth factors and factors hampering the market growth.4) The changing Injectable Drug Delivery Market structure, developing players, new item dispatch events, applications and topographical presence is reflected in this study.5) The latest industry plans and policies, market collaborations will enhance the strategic planning.

Read Full Details

Topics:
  • Business
  • Financial

Sunday, August 18


News

Lilly Eli & Co (LLY) Shareholder Atalanta Sosnoff Capital LLC Has Lowered Holding as Shares Declined

LLY

752.92 million shares or 10.33% less from 839.62 million shares in 2018Q4 were reported. Sheets Smith Wealth Mngmt invested 0.07% in Eli Lilly and Company (NYSE:LLY). Fort Washington Invest Advsrs Oh reported 32,459 shares. $50,281 worth of Eli Lilly and Company (NYSE:LLY) was bought by Smiley Joshua L. Atalanta Sosnoff Capital Llc decreased its stake in Lilly Eli & Co (LLY) by 4.82% based on its latest 2019Q1 regulatory filing with the SEC. Atalanta Sosnoff Capital Llc who had been investing in Lilly Eli & Co for a number of months, seems to be less bullish one the $106.70B market cap company.

Read Full Details

Topics:
  • Business
  • Financial
News

Better Buy: Eli Lilly vs. GlaxoSmithKline

LLY GSK +1 more LLY GSK GSK

Both big drugmakers have launched multiple new products to drive future growth while simultaneously dealing with sagging sales of older drugs. Lilly's rebates for insulin products Humalog and Humulin caused sales to slide. But there's plenty of good news for the company, too. These programs include several existing drugs for which Lilly hopes to win additional approved indications in addition to new drugs such as tanezumab, a pain medication that the company is codeveloping with Pfizer. This is a pretty good growth rate, especially viewed in the context of Lilly's dividend and its relatively attractive valuation, with shares trading at 16.5 times expected earnings.

Read Full Details

Topics:
  • Business
  • Health
  • Financial

Saturday, August 17


News

Coastal Investment Advisors Inc. Has $235,000 Stake in Eli Lilly And Co (NYSE:LLY) – Tech Know Bits

LLY

Schafer Cullen Capital Management Inc now owns 1,030,446 shares of the company’s stock valued at $111,587,000 after acquiring an additional 239,590 shares during the period. In related news, VP Michael J. Harrington sold 16,000 shares of the company’s stock in a transaction dated Monday, June 3rd. BMO Capital Markets boosted their target price on Eli Lilly And Co from $130.00 to $133.00 and gave the company an “outperform” rating in a research note on Wednesday, May 1st. Eli Lilly And Co has a fifty-two week low of $103.65 and a fifty-two week high of $132.13.

Read Full Details

Topics:
  • Business
  • Health
  • Financial
News

Rockland Trust Co. Boosts Position in Eli Lilly And Co (NYSE:LLY) – Tech Know Bits

LLY

Rockland Trust Co. lifted its position in Eli Lilly And Co (NYSE:LLY) by 1.4% in the 2nd quarter, according to the company in its most recent filing with the SEC. Several other large investors have also recently modified their holdings of LLY. Norges Bank acquired a new position in Eli Lilly And Co in the 4th quarter valued at approximately $1,056,086,000. Following the completion of the acquisition, the chief financial officer now directly owns 30,410 shares in the company, valued at $3,589,292.30. Edward Jones upgraded shares of Eli Lilly And Co from a “hold” rating to a “buy” rating and set a $117.49 target price on the stock in a research note on Tuesday, April 23rd.

Read Full Details

Topics:
  • Business
  • Health
  • Financial

Friday, August 16


News

Eli Lilly And Co (NYSE:LLY) Shares Sold by Cullen Frost Bankers Inc. – Mayfield Recorder

LLY

Cullen Frost Bankers Inc. trimmed its position in Eli Lilly And Co (NYSE:LLY) by 2.6% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 27,746 shares of the company’s stock after selling 729 shares during the quarter. In other news, CFO Joshua L. Smiley acquired 426 shares of the company’s stock in a transaction on Wednesday, June 5th. BMO Capital Markets boosted their price target on shares of Eli Lilly And Co from $130.00 to $133.00 and gave the company an “outperform” rating in a research note on Wednesday, May 1st.

Read Full Details

Topics:
  • Business
  • Financial
  • Health
News

South Street Advisors LLC Has Raised Position in Lilly Eli & Co (LLY) as Stock Declined

LLY

752.92 million shares or 10.33% less from 839.62 million shares in 2018Q4 were reported. Mitsubishi Ufj Tru & Bk has invested 0.44% of its portfolio in Eli Lilly and Company (NYSE:LLY). Rhenman And Prtn Asset Management has 1.5% invested in Eli Lilly and Company (NYSE:LLY) for 98,695 shares. Since February 19, 2019, it had 2 insider buys, and 5 insider sales for $128.51 million activity. The institutional investor held 91,080 shares of the major pharmaceuticals company at the end of 2019Q1, valued at $11.82M, up from 15,150 at the end of the previous reported quarter. South Street Advisors Llc who had been investing in Lilly Eli & Co for a number of months, seems to be bullish on the $106.42B market cap company.

Read Full Details

Topics:
  • Business
  • Financial
News

Cardinal Capital Management Sells 759 Shares of Eli Lilly And Co (NYSE:LLY) – Mayfield Recorder

LLY

The fund owned 46,919 shares of the company’s stock after selling 759 shares during the quarter. Eli Lilly And Co makes up approximately 1.5% of Cardinal Capital Management’s investment portfolio, making the stock its 23rd largest position. Geode Capital Management LLC now owns 13,108,002 shares of the company’s stock valued at $1,514,582,000 after purchasing an additional 830,689 shares during the period. Norges Bank acquired a new stake in Eli Lilly And Co in the fourth quarter valued at $1,056,086,000. Edward Jones raised shares of Eli Lilly And Co from a “hold” rating to a “buy” rating and set a $117.49 price target on the stock in a research report on Tuesday, April 23rd.

Read Full Details

Topics:
  • Business
  • Health
  • Financial